fintols

Johnson & Johnson vs Sanofi (JNJ vs SAN.PA)

Sanofi trades at 24.3x earnings vs 41.4x for Johnson & Johnson; Sanofi grows sales faster (+15.7% vs +5.9%). Margins, debt and dividend, Nov 2026.

Quick answer

On today's data (November 19, 2026): Sanofi looks cheaper on P/E: 24.3x against 41.4x for Johnson & Johnson. Sanofi grows faster: sales +15.7% against +5.9% for Johnson & Johnson in the latest quarter. Johnson & Johnson has the better net margin: 16.2% against 8.2% for Sanofi.

This is a snapshot of the numbers, not a recommendation to buy or sell.

Analyze Johnson & Johnson freeAnalyze Sanofi free

Your first analysis is free with a free account, no card.

Short answer

On P/E as of November 19, 2026, Johnson & Johnson is the more expensive of the two: it trades at 41.4x its annual earnings against 24.3x for Sanofi. Johnson & Johnson reports two segments. Innovative Medicine, the larger, sells drugs such as Darzalex, Stelara, Tremfya, Erleada and Carvykti across oncology, immunology and neuroscience. Sanofi is a drugmaker focused on its Biopharma business: specialty medicines for immunology, rare diseases and neurology, led by Dupixent, its top-selling product, plus flu, pediatric and booster vaccines. What helps read that gap: Johnson & Johnson sales +5.9% against +15.7% for Sanofi in the latest quarter; net margin 16.2% against 8.2%; net debt for Johnson & Johnson: 0.8x EBITDA against 0.9x EBITDA. A higher P/E is not by itself a buy or a sell signal: it is a snapshot of today.

Johnson & Johnson (JNJ) and Sanofi (SAN.PA) compete in healthcare and pharma. Here are Johnson & Johnson and Sanofi side by side with their real figures as of November 19, 2026: what sets them apart, which fits each kind of investor and the most common questions, without telling you whether to buy Johnson & Johnson or Sanofi.

Johnson & Johnson vs Sanofi: the figures

FigureJohnson & JohnsonSanofi
Share price$272.70 (November 18, 2026)€84.08 (November 19, 2026)
Market cap$656.5 billion€100.9 billion
P/E (TTM)41.4x24.3x
Forward P/E23.5x8.8x
Revenue growth (quarter)+5.9%+15.7%
Net margin (TTM)16.2%8.2%
Net debt / EBITDA0.8x0.9x
Dividend yield1.97%4.76%
Beta0.200.26

Johnson & Johnson and Sanofi figures from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 19, 2026; N/A means that Johnson & Johnson or Sanofi figure is not available, and we never estimate it.

3 key differences between Johnson & Johnson and Sanofi

  1. Valuation: Johnson & Johnson trades at 41.4x its annual earnings and Sanofi at 24.3x; the market pays more for each dollar of Johnson & Johnson profit, usually because it expects more growth.
  2. Dividend: Sanofi yields 4.76% at today's price and Johnson & Johnson yields 1.97%.
  3. Profitability: for every 100 of sales, Johnson & Johnson keeps 16.2 as net profit and Sanofi keeps 8.2.

Johnson & Johnson or Sanofi: which fits your profile

Neither Johnson & Johnson nor Sanofi wins on everything, and owning both is also an option: spreading money across several companies or an index fund reduces what rides on each one.

Verdict: Johnson & Johnson or Sanofi?

Of the 6 comparable figures in the table, Johnson & Johnson stands out on 3 (net margin, less debt over EBITDA and lower volatility (beta)) and Sanofi stands out on 3 (sales growth, lower P/E and dividend yield). That does not name a winner between Johnson & Johnson and Sanofi: the table is a snapshot of today, not a forecast.

You are halfway through

Keep reading free.

Create your free account to continue reading “Johnson & Johnson vs Sanofi (JNJ vs SAN.PA)”.

No card required

That easy

Three steps. Zero spreadsheets.

  1. 1Search a companyBy the name you know it: Apple, Inditex, Santander… ETFs too.
  2. 2Fintols does the homeworkIt reads the official filings, runs the numbers and writes the analysis for you.
  3. 3You analyze and decideWith the five answers clear, you decide. And you save the analysis to review it when the price moves.
Analyze any stock free
Analyze JNJ free